University of Genoa
Dipartimento di Scienze della Salute (DiSSal)
Andrea Orsi, born in Genoa on July 20, 1980, obtained a Master Degree in Medicine and Surgery, a Postgraduate Course Diploma in Hygiene and Preventive Medicine and the PhD in Epidemiology and Prevention (vaccine prevention address) at the University of Genoa. Since November 2019 he works as Associate Professor in General and Applied Hygiene at the Department of Health Sciences, University of Genoa. His main research interests concern the study of microorganisms applied to Hygiene and Public Health and especially to clinical and molecular epidemiology and the prophylaxis of communicable diseases of pre-eminent interest for Public Health. The main fields of research concern molecular epidemiology and virology applied to hygiene with particular attention to the study of molecular techniques aimed at preventing infections. These studies involved infectious diseases with a high social impact such as influenza, minor respiratory infections, viral hepatitis, infectious gastroenteritis, measles, rubella and congenital rubella. Other research fields concern the surveillance and control of Healthcare-Associated Infections (HAIs) in the hospital setting and the surveillance and control of antimicrobial resistance. Prof. Orsi is the author of 114 scientific publications in peer-reviewed international journals, with 1850 citations and an H index of 23 (source Scopus).

Presenter of 1 Presentation

O078 - PREVALENCE OF PNEUMOCOCCAL SEROTYPES CAUSING COMMUNITY-ACQUIRED PNEUMONIA IN THE ELDERLY IN ITALY USING URINARY ANTIGEN DETECTION TEST: THE PUMA STUDY, 2017-2020 (ID 433)

Session Type
Parallel Session
Date
Wed, 22.06.2022
Session Time
15:05 - 16:35
Room
Birchwood Ballroom
Lecture Time
16:20 - 16:30

Abstract

Background

In Italy, pneumococcal conjugate vaccines (PCVs) have been included in the National Immunization Program for infant since 2005 (PCV13 since 2010) and for adults aged ≥50 years since 2011. Our study assessed pneumococcal serotype distribution of community-acquired pneumonia (CAP) among older adults hospitalized from September 2017 to February 2020.

Methods

PUMA was a 3-year cohort study that enrolled adults aged ≥65 years old, hospitalized with clinical and radiographically confirmed CAP in 8 hospital centres from 4 Italian regions (Veneto, Liguria, Apulia and Sicily). Pneumococcus was identified using serotype-specific urinary antigen detection assays (UAD 1/2) and BinaxNow®. UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in 23-valent pneumococcal polysaccharide vaccine (PPV23).

Results

Among 1155 hospitalized CAP patients, 59.2% were male and 51.5% were ≥80 years old. Overall, 92.2% of patients had ≥1 pre-existing risk factor for CAP: most frequently chronic obstructive pulmonary disease (33.3%), chronic cardiac disease (32.6%), and diabetes mellitus (30.0%). 21.7% of CAP patients had been ever vaccinated with PCV13 only (8.1%), PPV23 only (6.8%) or both (6.8%). Pneumococcus was identified in 144 patients (12.5%). 73.6% of pCAP was caused by a non-PCV13 serotype (Table 1).

figure 1.jpg

Conclusions

In the context of high pediatric and limited adult PCV13 immunization, older adult vaccine-serotype CAP has declined, although serotype 3 remains the most frequent serotype identified. Non-vaccine serotypes now cause most hospitalized pCAP in older adults, often from serotypes in newer expanded valency PCVs (PCV15 and PCV20) recently licensed in the United States.

Hide